VAXNEUVANCE susp inj ser pré 0.5 ml
7680687520010
CH-68752
J07AL02
08.08.
Reimbursement limitations:
0808 NEU
La prise en charge des coûts des vaccins au titre de mesure préventive dans le …
1 / 3
google
Details
- Product number
- 6875201
- CPT
- -
- Packaging group
- 1
- Unit
- Fertigspritze(n)
- Composition
- polysaccharida streptococci pneumoniae typus 1 conjugata cum proteino corynebacteriae diphtheriae CRM 197 2 µg et polysaccharida streptococci pneumoniae typus 3 conjugata cum proteino corynebacteriae diphtheriae CRM 197 2 µg et polysaccharida streptococci pneumoniae typus 4 conjugata cum proteino corynebacteriae diphtheriae CRM 197 2 µg et polysaccharida streptococci pneumoniae typus 5 conjugata cum proteino corynebacteriae diphtheriae CRM 197 2 µg et polysaccharida streptococci pneumoniae typus 6A conjugata cum proteino corynebacteriae diphtheriae CRM 197 2 µg et polysaccharida streptococci pneumoniae typus 6B conjugata cum proteino corynebacteriae diphtheriae CRM 197 4 µg et polysaccharida streptococci pneumoniae typus 7F conjugata cum proteino corynebacteriae diphtheriae CRM 197 2 µg et polysaccharida streptococci pneumoniae typus 9V conjugata cum proteino corynebacteriae diphtheriae CRM 197 2 µg et polysaccharida streptococci pneumoniae typus 14 conjugata cum proteino corynebacteriae diphtheriae CRM 197 2 µg et polysaccharida streptococci pneumoniae typus 18C conjugata cum proteino corynebacteriae diphtheriae CRM 197 2 µg et polysaccharida streptococci pneumoniae typus 19A conjugata cum proteino corynebacteriae diphtheriae CRM 197 2 µg et polysaccharida streptococci pneumoniae typus 19F conjugata cum proteino corynebacteriae diphtheriae CRM 197 2 µg et polysaccharida streptococci pneumoniae typus 22F conjugata cum proteino corynebacteriae diphtheriae CRM 197 2 µg et polysaccharida streptococci pneumoniae typus 23F conjugata cum proteino corynebacteriae diphtheriae CRM 197 2 µg et polysaccharida streptococci pneumoniae typus 33F conjugata cum proteino corynebacteriae diphtheriae CRM 197 2 µg corresp. polysaccharida 32 µg et proteinum corynebacteriae diphtheriae CRM 197 ca. 30 µg, adjuvans: aluminium 0.125 mg ut aluminii phosphas, natrii chloridum corresp. natrium 1.77 mg, histidinum, polysorbatum 20, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml.
Articles (1)
Vaxneuvance, Injektionssuspension
Injektionssuspension
1
Official Swissmedic V2 data
Additional information from the official database
Official medical documents
Detailed composition
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
(N/A)
|
2.0 UG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
2.0 UG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
2.0 UG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
2.0 UG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
2.0 UG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
4.0 UG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
2.0 UG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
2.0 UG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
2.0 UG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
2.0 UG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
2.0 UG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
2.0 UG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
2.0 UG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
2.0 UG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
2.0 UG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
32.0 UG | Substance | WIIS |
|
(N/A)
|
- | Substance | WIIS |
|
(N/A)
|
0.125 MG | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
1.77 MG | Substance | HBESI |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
Reimbursement information
Public price
CHF 79.80
Specialties list
Yes
Generic
No
Reimbursement limitation
SL addition date:
01/04/2023
Authorization holder
MSD Merck Sharp & Dohme AG
6005 Luzern
Authorization information
- Swissmedic authorization number
- 68752
- Drug name
- Vaxneuvance, Injektionssuspension
- Galenic form
- INJFS
- ATC Code
- J07AL02
- Authorization status
- Z
- Dispensation category
- B
- First authorization
- 14/02/2023
- Authorization expiration date
- 13/02/2028
- IT number
- 08.08.
- Domain
- Human medicine
Packaging details
- Description (FR)
- VAXNEUVANCE sol inj 2 µg 1 pce
- Description (DE)
- VAXNEUVANCE Inj Lös 2 µg 1 Stk
- Market launch
- 14/02/2023
- Narcotic (BTM)
- No